At the time of writing, Roivant Sciences Ltd [ROIV] stock is trading at $10.83, down -0.73%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ROIV shares have gain 1.03% over the last week, with a monthly amount drifted -1.01%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Roivant Sciences Ltd [NASDAQ: ROIV] stock has seen the most recent analyst activity on February 15, 2024, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $17. Previously, Piper Sandler started tracking the stock with Overweight rating on January 05, 2024, and set its price target to $20. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $14 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $17 on October 17, 2023. BofA Securities initiated its recommendation with a Neutral and recommended $10.50 as its price target on June 08, 2023. JP Morgan started tracking with a Overweight rating for this stock on October 27, 2022, and assigned it a price target of $7. In a note dated May 23, 2022, SVB Leerink initiated an Outperform rating and provided a target price of $6 on this stock.
For the past year, the stock price of Roivant Sciences Ltd fluctuated between $8.24 and $13.24. Currently, Wall Street analysts expect the stock to reach $15.83 within the next 12 months. Roivant Sciences Ltd [NASDAQ: ROIV] shares were valued at $10.83 at the most recent close of the market. An investor can expect a potential return of 46.17% based on the average ROIV price forecast.
Analyzing the ROIV fundamentals
According to Roivant Sciences Ltd [NASDAQ:ROIV], the company’s sales were 124.80M for trailing twelve months, which represents an 5.68% jump. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at 38.42%, Pretax Profit Margin comes in at 34.08%, and Net Profit Margin reading is 34.85%. To continue investigating profitability, this company’s Return on Assets is posted at 0.6, Equity is 1.25 and Total Capital is 0.69. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.70 points at the first support level, and at 10.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.99, and for the 2nd resistance point, it is at 11.15.
Ratios To Look Out For
It is important to note that Roivant Sciences Ltd [NASDAQ:ROIV] has a current ratio of 25.24. Further, the Quick Ratio stands at 25.10, while the Cash Ratio is 24.5. Considering the valuation of this stock, the price to sales ratio is 64.11, the price to book ratio is 1.46 and price to earnings (TTM) ratio is 2.14.
Transactions by insiders
Recent insider trading involved Venker Eric, President & COO, that happened on Feb 09 ’24 when 96950.0 shares were sold. 10% Owner, Ramaswamy Vivek completed a deal on Jan 02 ’24 to sell 3.0 million shares. Meanwhile, Chief Operating Officer Venker Eric sold 0.15 million shares on Oct 05 ’23.
